Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2, Safety and Efficacy Study of Isatuximab, an Anti-CD38 Monoclonal Antibody, Administered by Intravenous (IV) Infusion in Patients With Relapsed or Refractory T-acute Lymphoblastic Leukemia (T-ALL) or T-lymphoblastic Lymphoma (T-LBL)

NCT02999633 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT02999633
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02999633 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2, Safety and Efficacy Study of Isatuximab, an Anti-CD38 Monoclonal Antibody, Administered by Intravenous (IV) Infusion in Patients With Relapsed or Refractory T-acute Lymphoblastic Leukemia (T-ALL) or T-lymphoblastic Lymphoma (T-LBL)
Lead sponsor
Sanofi
Phase
Phase 2
Overall status
Terminated
Start date
March 8, 2017
Completion date
November 14, 2017
Enrollment
14 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

t-cell type acute leukemia-precursor, t-lymphoblastic lymphoma/leukaemia